MiR-223 is increased in lungs of patients with COPD and modulates cigarette smoke-induced pulmonary inflammation
- 1 December 2021
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 321 (6) , L1091-L1104
Abstract
Since microRNA (miR)-223-3p modulates inflammatory responses and chronic obstructive pulmonary disease (COPD) is associated with amplified pulmonary inflammation, we hypothesized that miR-223-3p plays a role in COPD pathogenesis. Expression of miR-223-3p was measured in lung tissue of two independent cohorts with patients with GOLD stage II–IV COPD, never smokers, and smokers without COPD. The functional role of miR-223-3p was studied in deficient mice and on overexpression in airway epithelial cells from COPD and controls. We observed higher miR-223-3p levels in patients with COPD stage II–IV compared with (non)-smoking controls, and levels were associated with higher neutrophil numbers in bronchial biopsies of patients with COPD. MiR-223-3p expression was also increased in lungs and bronchoalveolar lavage of cigarette smoke (CS)-exposed mice. CS-induced neutrophil and monocyte lung infiltration was stronger in miR-223-deficient mice on acute (5 days) exposure, but attenuated on subchronic (4 wk) exposure. Additionally, miR-223 deficiency attenuated acute and subchronic CS-induced lung infiltration of dendritic cells and T lymphocytes. Finally, in vitro overexpression of miR-223-3p in non-COPD airway epithelial cells suppressed C-X-C motif chemokine ligand 8 (CXCL8) and granulocyte monocyte-colony stimulation factor (GM-CSF) secretion and gene expression of the proinflammatory transcription factor TRAF6. Importantly, this suppressive effect of miR-223-3p was compromised in COPD-derived cultures. In conclusion, we demonstrate that miR-223-3p is increased in lungs of patients with COPD and CS-exposed mice and is associated with neutrophilic inflammation. In vivo data indicate that miR-223 acts as negative regulator of acute CS-induced neutrophilic and monocytic inflammation. In vitro data suggest that miR-223-3p does so by suppressing proinflammatory airway epithelial responses, which is less effective in COPD epithelium.Keywords
Funding Information
- AstraZeneca
- Chiesi | Chiesi Foundation
- UGent | Bijzonder Onderzoeksfonds UGent (BOF/GOA 01G00819)
- U4 Project (BOF 05U40516)
- Fund for Scientific Research in Flanders (G025218N, 3G041819, G0G23182)
This publication has 44 references indexed in Scilit:
- MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitmentJournal of Clinical Investigation, 2013
- Macrophage microvesicles induce macrophage differentiation and miR-223 transferBlood, 2013
- New insights into the immunology of chronic obstructive pulmonary diseaseThe Lancet, 2011
- MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiationNature Immunology, 2010
- MicroRNAs as modulators of smoking-induced gene expression changes in human airway epitheliumProceedings of the National Academy of Sciences, 2009
- Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPDThorax, 2009
- MicroRNAs: new regulators of immune cell development and functionNature Immunology, 2008
- Mitochondrial Localization and Function of Heme Oxygenase-1 in Cigarette Smoke–Induced Cell DeathAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- MicroRNAs Modulate Hematopoietic Lineage DifferentiationScience, 2004
- NMR Solution Structure of Murine CCL20/MIP-3α, a Chemokine That Specifically Chemoattracts Immature Dendritic Cells and Lymphocytes through Its Highly Specific Interaction with the β-Chemokine Receptor CCR6Journal of Biological Chemistry, 2001